Treatment with SGLT2 inhibitors (1) lowered glucose level from 2 h after administration of the first dose, (2) improved the variation in blood glucose level by 1 week after the commencement of treatment, and (3) did not increase the incidence of hypoglycemia after 1 week. The gene discussed is SLC5A2; the disease is Hypoglycemia.